 OP-1250 in combination with palbociclib was well-tolerated in patients with ERHER2- breast cancer, with no dose-limiting toxicities, and no observed drug-drug interaction No induced metabolism of palbociclib and no safety interaction was observed Overall tolerability profile of the combination consistent with the FDA-approved label of palbociclib plus an endocrine agent Phase 2 dose expansion of ... The post Olema Oncology Announces OP-1250 Demonstrates Attractive Combinability with CDK 46 In... 